Hypoxia-induced changes of seizure susceptibility in immature rats are modified by vigabatrin

Hana Kubová, Pavel Mareš
Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic

ABSTRACT – The effects of hypoxia on susceptibility to pentylenetetrazol (PTZ)-induced seizures were assessed in juvenile rats. Animals at postnatal (P) day 25 were exposed to hypobaric hypoxia (simulated altitude of 7 000 m) for 8 h PTZ in a dose of 100 mg/kg was injected 1, 3 or 7 days later and latency, pattern and severity of seizures were registered. Mortality due to seizures was also evaluated. Two seizure types were evaluated: minimal mostly clonic seizures (mMS) and generalized tonic clonic seizures (GTCS). To study protective effects of vigabatrin (600 mg/kg, i.p.), drug was injected either 24 h before or immediately after hypoxia exposure. Non-hypoxic animals of corresponding age were used for comparison as controls. In non-hypoxic controls, administration of vigabatrin had pro-convulsive effects in intervals from 3 days up to 1 week – incidence of GTCS increased by 56-57%. Hypoxia exposure resulted to increased seizure susceptibility three days later, incidence of generalized tonic clonic seizures increased by 60% and latency to both seizure types shorter than in non-hypoxic controls. Also, mortality due to seizures was higher (by 58%). In other intervals, there was no difference between hypoxic and non-hypoxic animals. Vigabatrin administered 24 h before hypoxia led to significant decrease of seizure-induced mortality in intervals 1 and 3 days. Administration of vigabatrin immediately after hypoxia exposure resulted in decreased seizure severity when assessed 3 days later. Our data suggest that hypobaric hypoxia transiently increases seizure susceptibility. This effect is partially abolished by vigabatrin administered after hypoxia exposure.

Key words: immature brain, hypobaric hypoxia, vigabatrin, pentylenetetrazol-induced seizures

Hypoxia is one of the most important causes of seizure development and impairment of brain functions in the immature brain (Calvert and Zhang 2005). Some experimental studies suggest that hypoxia or hypoxia/ischemia leads to seizure development or to increased seizure susceptibility. In other studies, protective effects of hypoxia preconditioning have been documented. Patterns of changes of seizure susceptibility depend on many variables (Kelly 2002). Severity and duration of insult as well as the model used of seizures are the most important factors affecting outcome. The level of the brain maturation at the time of the hypoxic/ischemic insult is also another key factor which affects seizure susceptibility. In immature rats, there are periods of increased seizure susceptibility after exposure to hypoxia or hypoxia/ischemia. The exact age...
when such “developmental windows of increased seizure susceptibility” occurs seems to be related to the model of insult used. Exposure to global hypoxia (15–20 min, 3–4% O₂) induces seizure activity in rat pups aged 10–12 days (P10-12) but not younger or older (Jensen and Wang 1996). In contrast, increased excitability of sensorimotor cortex was observed in P12, P25 as well as P35 rats exposed to hypobaric hypoxia (stimulated altitude of 7 000 m lasted for 1h) and stimulated 15 min after the end of hypoxia exposure (Kalinčík and Marešová 2005). There are however no data on the time-course of this proconvulsant effect of hypobaric hypoxia in immature rats. Sensitivity to chemoconvulsants has not yet been tested in this model. The evidence from experimental studies suggests that enhancing the function of the major inhibitory neurotransmitter (GABAergic) system can result in neuroprotection. Green et al. (2000) have suggested three reasons why increasing GABA function might be a beneficial therapeutic approach to hypoxia/ischemia. Firstly, biochemical studies have demonstrated that despite an increase of extracellular GABA level in hypoxic tissue, GABA synthesis and release is impaired during an ischemic insult. Secondly, increased glutamatergic activity might itself decrease GABAergic functions. Thirdly, enhancement of GABAergic function is neuroprotective and can prevent or reduce neuronal death. In addition, an increase of GABA inhibition suppresses epileptic activity (Rho and Sankar 1999) and thus treatment with GABAergic drugs might prevent the development of hypoxia-induced seizures or increased excitability. Experimental data on these possible effects are however rare.

We designed a series of experiments to address the following questions: 1) does exposure to hypoxia change susceptibility to chemically induced seizures in immature rats and what is time-course of these changes? 2) Can a vigabatrin-induced increase of GABA level before or immediately after hypoxia exposure prevent changes of seizure susceptibility, seizure pattern and/or seizure outcome at different time-points after hypoxia?

**Methods**

Experiments were performed in male Wistar albino rats on postnatal day 25 (P25; n = 190). Experimental groups consisted from 8 to 17 animals. The day of birth was defined as day 0. Rats were housed in a controlled environment (temperature 22 ± 1°C, humidity 50-60%, lights on 0600 – 1800 h) with free access to food and water. Experiments were approved by the Animal Care and Use Committee of the Institute of Physiology of the Academy of Sciences of the Czech Republic. Animal care and experimental procedures were conducted in accordance with the guidelines of the European Community Council directive 86/609/EEC.

The effects of vigabatrin (VGB, gamma-vinyl-GABA; generous gift from Aventis, former Hoechst Marion Roussel) on hypoxia-induced changes of seizure susceptibility were studied in a model of pentylenetetrazol-induced convulsions in two experimental schedules: VGB, freshly dissolved in physiological saline (300 mg/mL), was injected in a dose of 600 mg/kg i.p. before and/or after hypoxia exposure.

**Vigabatrin pretreatment**

Experimental animals (n = 68) received VGB at P24, controls (n = 75) were injected with a corresponding volume of physiological saline (2 mL/kg). Twenty four hours later (at P25) animals from both control and experimental group were randomly divided into two subgroups and one control and one experimental subgroup was exposed to hypobaric hypoxia (stimulated altitude of 7 000 m) for 8 h. Decompression and compression took approximately 12 minutes, during which temperature of the hypobaric chamber was maintained at 22-23°C. During hypoxia exposure, the behavior of animals was monitored by an experienced observer. Other 2 subgroups were kept in the animal room at the same temperature and served as non-hypoxic controls.

To induce convulsions, animals from all four groups were injected with pentylenetetrazol (Sigma, 80 mg/kg s.c.) one, 3 or 7 days later, i.e. at P26, P28 or P32. After PTZ injection, animals were individually placed in a plexiglas cages and their behavior was monitored for 30 minutes. Incidence and latency of two types of convulsive seizures, minimal (mMS) i.e. predominantly clonic convulsions involving head and forelimb muscles with preserved righting reflexes, and generalized tonic-clonic seizures (GTCS), starting with short running phase and accompanied by a loss of righting reflexes were registered. The incidence of complete tonic phase involving all four limbs or partial tonic phase involving only forelimbs was registered separately. To assess severity of epileptic phenomena animals were assigned a score for the most severe behavioral characteristics as follows (Pohl and Mareš 1987): 0 = no changes, 0.5 = abnormal behavior (e.g. automatism, increased orienting reaction), 1 = isolated myoclonic jerks, 2 = atypical or incomplete minimal seizures, 3 = minimal seizures, 4 = generalized seizures without the tonic phase, 5 complete generalized tonic-clonic seizures.

Mortality was also registered and evaluated.

**Vigabatrin posttreatment**

Another group of animals was exposed to 8 h hypobaric hypoxia at P25 (n = 23). After the end of hypoxic insult, animals were randomly divided into 2 subgroups. Animals from one of them were injected with vigabatrin...
GTCS was higher in hypoxic than in non-hypoxic animals vs 3.35 ± 4.0 s; p = 0.02) and at P32 (i.e. 8 days after VGB injection; score 4.5 ± 0.5 vs 2.4 ± 0.4; p = 0.019). VGB injected 2, 3, 4, or 8 days before PTZ increased incidence of GTCS compared to corresponding saline treated controls by 56–57% (p < 0.01 [figure 1]). Incidence of complete tonic phase was higher in animals receiving VGB at P24 and PTZ 4 or 8 days later (increase by 44% and 68%, respectively; p < 0.05). Minimal, clonic seizures were not significantly affected by VGB and mortality remained unchanged in all groups (figure 2).

Effects of vigabatrin in non-hypoxic rats

In general, VGB pretreatment increased sensitivity to PTZ-induced seizures. Seizure severity was significantly higher in rats exposed to PTZ at P28 (score 5 ± 0 vs 3.7 ± 0.3; p = 0.02) and at P32 (i.e. 8 days after VGB injection; score 4.5 ± 0.5 vs 2.4 ± 0.4; p = 0.019). VGB injected 2, 3, 4, or 8 days before PTZ increased incidence of GTCS compared to corresponding saline treated controls by 56–57% (p < 0.01 [figure 1]). Incidence of complete tonic phase was significantly lower in animals tested one day after hypoxia (P25 + 1) compared to corresponding controls (8% vs 69%; p < 0.0001 [figure 1A]). Mortality was abolished by VGB in animals tested one day after hypoxia (group 25 + 1, 0% vs 46% in controls; p = 0.007) and decreased in animals tested 3 days after the hypoxic insult compared to controls (25 + 3, 25% vs 87.5%; p = 0.02 [figure 1A]).

Effects of vigabatrin in rats exposed to hypoxia

Effects of pre-treatment

There was no difference between VGB pretreated and non-treated hypoxic animals in score expressing seizure severity. Pretreatment with VGB 24 h before hypoxia exposure prolonged latencies of minimal seizures one and 3 days after hypoxia. Incidence of GTCS was not affected by VGB pretreatment at any interval, but incidence of complete tonic phase was significantly lower in animals tested one day after hypoxia (P25 + 1) compared to corresponding controls (8% vs 69%; p < 0.0001 [figure 1A]). Mortality was abolished by VGB in animals tested one day after hypoxia (group 25 + 1, 0% vs 46% in controls; p = 0.007) and decreased in animals tested 3 days after the hypoxic insult compared to controls (25 + 3, 25% vs 87.5%; p = 0.02 [figure 1A]).

Effects of post-treatment

VGB injected immediately after hypoxia exposure prolonged latencies of minimal seizures (106 ± 11 s vs 319 ± 49 s; p = 0.009). Neither latency nor incidence of GTCS were affected by VGB post-treatment, but the incidence of complete tonic phase was significantly lower in animals with VGB than in corresponding controls (7% vs 87.5%; p < 0.001 [figure 1B]). In addition, VGB post-treatment tended to suppress mortality during PTZ-induced seizures (47% vs 87.5% in controls; p = 0.06 [figure 1B]).

Discussion

The data reported here demonstrate a transient increase of susceptibility to PTZ-induced seizures in P25 rats exposed to hypobaric hypoxia. Previously published studies suggested that episodes of brain hypoxia/ischemia may alter seizure susceptibility in a different way and both seizure protection and proconvulsive effects have been documented. The detailed condition necessary to confer decrease or increase of seizure susceptibility are not yet understood.
**Figure 1.** Incidence of generalized tonic-clonic seizures (left graphs; black bars - GTCS with complete tonic phase; striped bars - GTCS with tonic phase restricted to forelimbs; white bars - generalized clonic seizures) and mortality (right graphs) after PTZ injection (80 mg/kg sc).

**A** Animals pretreated with vigabatrin in a single dose of 600 mg/kg 24 h before exposure to hypobaric hypoxia and corresponding controls. From top to bottom: rats 1, 3 and 7 days after hypoxia.

**B** Animals injected with vigabatrin (600 mg/kg) immediately after the exposure to hypoxia and injected with PTZ 3 days after hypoxia and corresponding controls. Incidence of generalized seizures in left graphs, incidence of lethal outcome in right graphs.

PTZ: non-hypoxic controls receiving only PTZ; VGB+PTZ: non-hypoxic animals receiving vigabatrin at P24 and PTZ at different intervals; HYP+PTZ: rats exposed to hypoxia and given PTZ 1, 3 and/or 7 days later; VGB+HYP+PTZ: rats pretreated with VGB at P24, exposed to hypoxia at P25 and given PTZ 1, 3 or 7 days after hypoxia. * (p < 0.05) denotes difference in the incidence of seizures and/or mortality; # denotes difference in the incidence of complete tonic phase involving both forelimbs and hindlimbs (left side of the panels) compared to corresponding controls; Student’s t-test.
known. Duration and severity of ischemic/hypoxic insult, chosen model and presence of morphological damage seem to play important role in the outcome of the insult (Vanický et al. 1997; Rubaj et al. 2003). Mechanisms used to induce seizures after hypoxia/ischemia are also important. In a model of forebrain ischemia, decreased sensitivity to lidocaine- and PTZ-induced seizures was observed shortly after insult, whereas threshold for NMDA-induced seizures decreased in the same interval (Kim and Todd 1999). In present study increased severity of PTZ-induced seizures and mortality due to seizures was observed three days after hypoxia exposure. There is however some controversy between our and previously published data which show an increase of threshold for PTZ-induced

Figure 2. Latencies of two types of seizures elicited by pentylenetetrazol (mean ± S.E.M.). On the left side of panels there are latencies of minimal clonic seizures (mMS), the right side of the panels demonstrates latencies of generalized tonic-clonic seizures (GTCS). Abscissae: the 4 groups as in figure 1; ordinates: latencies to seizure onset in seconds.
seizures in adult rats exposed to ischemia/hypoxia insult (Rubaj et al. 2000; Kim and Todd 1999). Such differences may be explained by the different intervals between the insult and injection of PTZ (6 h – 1 week) and also by insults used. Both above mentioned studies used models of more severe hypoxia/ischemia accompanied either by seizures during hypoxia exposure (Rubaj et al. 2003) or by a neuronal loss (Kim and Todd 1999). In contrast, exposure to hypobaric hypoxia did not lead to seizures and previously published studies did not report significant neuronal loss in this model (Fischer et al. 1974). Also, the level of brain maturation at the time of insult (adults vs prepubescent animals) can play crucial role in changes of seizure susceptibility. Jensen et al. (1991) reported highly age-related hyperexcitability in model of global hypoxia in immature rats. In their study model, seizure activity and permanent hyperexcitability were seen in rats exposed to hypoxia at P10-12 but not younger (P5) or older (P60) rats (Jensen et al. 1996). On the other hand, in a model of hypobaric hypoxia, increased susceptibility to electrically-induced seizures was observed immediately after the insult in P12 -35 rats (Kalinčík and Marešová 2005) suggesting that these changes of seizure susceptibility may be less age-specific. Present data demonstrate hypobaric hypoxia-induced changes in susceptibility to PTZ-induced seizures only in one group of immature rats. Therefore we cannot exclude the possibility that even small changes in sensitivity to PTZ with age play a role. This possibility requires further study.

PTZ induces two different types of convulsive seizures and various seizure parameters can be evaluated in individual animals (Velšek et al. 1992). Minimal clonic and generalized tonic-clonic seizures are generated in different structures. Minimal, predominantly clonic seizures originate in the forebrain whereas generalized tonic-clonic seizures in the brainstem and/or spinal cord (Browning and Nelson 1986; Mareš 2006). Shortening of latencies in both minimal and generalized tonic-clonic seizures in hypoxic animals indicate involvement of different brain structures. In non-hypoxic animals, pre-treatment with vigabatrin increased severity of PTZ-induced seizures in intervals longer than 48 hours after administration. In intervals from 3 to 8 days, the incidence of generalized seizures and mortality due to seizures were significantly higher compared to untreated controls. In our previous study, vigabatrin in doses 300-1200 mg/kg decreased incidence of complete tonic phase of PTZ-induced seizures in P25 rats 4 and 24 h after administration (Haugvícová et al. 2002). This is in contrast to data from other laboratories where anticonvulsant effects of vigabatrin seem to be related to the used model, dose and interval after administration (Dalby and Nielsen 1997; Vinogradova et al. 2005). In addition, some reports showed that vigabatrin possesses both anti- and proconvulsant properties in various models of epileptic seizures; proconvulsant effects are however more frequently seen at shorter intervals after vigabatrin administration and/or after doses higher than those used in present study (Löscher et al. 1989; Mareš and Šlamberová 2004, Stuchlík et al. 2001; Luszczki and Czuczwar 2007). As demonstrated both in vivo and in vitro, vigabatrin is an irreversible inhibitor of brain 4-aminobutyrate-2-ketoglutarate aminotransferase (GABA-T; Lippert et al. 1977; Sarup et al. 2003). After a single dose of vigabatrin (200 mg/kg) in adult rats, GABA increase was maintained until 48h with partial recovery at 3 days after drug injection (Valdizán et al. 1999). There is however no direct correlation between GABA level in the brain and seizure protection (Bernaconi et al. 1988; Löscher et al. 1989), because substantially increased brain GABA levels were found already one or two hours after vigabatrin administration when the seizure protection is low. On the other hand, exposure of various brain structures to increased GABA levels may result in “GABA withdrawal syndrome” on cessation. Previously studies have shown that the withdrawal of GABA after brief but sustained administration leads to increased seizure susceptibility or seizure development (Brailowsky et al. 1987). In adult rats, withdrawal of GABA infusion lasting for 6 h was sufficient to elicit epileptiform activity (Brailowsky et al. 1988). The recovery period, i.e. the disappearance of epileptiform activity and seizures, lasted from 1 to 10 days (Brailowsky et al. 1990). The increased seizure severity seen three and more days after the vigabatrin administration in our study might be therefore explained as the rebound of excitability.

Partially protective effects of vigabatrin post-treatment against hypoxia-induced increase of seizure susceptibility and mortality are difficult to understand. Neuroprotective effects of vigabatrin, expressed as decreased severity of the damage in various brain areas, were documented in ischemia-induced brain damage 1 week after injury (Shuaib et al. 1996). As mentioned above, quantitative changes in the cytoarchitecture of the brain were not described in a model used in our study, but some quantitative changes of the microstructure of the hippocampus and sensorimotor cortex occurred after hypobaric hypoxia (Fischer et al. 1980a, b; Pokorny et al. 1982). However, it is not clear whether these changes may play a role in hypoxia-induced seizure susceptibility and whether they can be affected by vigabatrin. At the same time point when protective effects of vigabatrin were observed in hypoxic animals, increased seizure severity (proconvulsant effects) and seizure-induced mortality occurred in non-hypoxic animals. Explanation for this effect is purely speculative. Cerebral ischemia was found to result in an increase of GABA concentration with concomitant inhibition of GABA synthesis and release. Following hypoxia, GABA function can therefore decrease and this may participate in changes of seizure susceptibility. Effects of vigabatrin on GABA levels might therefore normalize hypoxia-induced disbalance of the inhibitory system.
In conclusion, our results demonstrated protective effects of vigabatrin administered after mild hypoxia against hypoxia-induced changes of seizure susceptibility in juvenile rats. Mechanisms responsible for these protective effects remain to be analyzed.

Acknowledgements. The authors would like to express thanks to the late Milan Mluvka for excellent technical assistance. This study was supported by a grant from Hoechst Marion Roussel (Aventis), No 304/05/2582 of the Grant Agency of the Czech Republic (H.K.), and by Research Project AV0Z 50110509.

References


Fischer J, Jilek L, Trojan S. Qualitative and quantitative neurohistological changes produced in the rat brain by prolonged aero

Fischer J, Langmeier M, Trojan S. Changes in the length and width of the postsynaptic density, the width of the intersynaptic density and the synaptic cleft in the cerebral cortex synapses of rats exposed to prolonged aero


Haugvicová R, Kubová H, Mareš P. Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced sei


Lippert B, Metcalf BW, Jung MJ, Casara P. 4-amino-hex-5-enoi acid, a selective catalytic inhibitor of 4-aminobutyric-acid ami


Luszczki JI, Czuczwar SJ. Isobolographic characterization of in


Pohl M, Mareš P. Effects of flunarizine on Metrazol-induced sei


